Literature DB >> 19913659

The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder.

Davide Martino1, Giovanni Defazio, Gavin Giovannoni.   

Abstract

Diagnosis and treatment of the PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) variant of Gilles de la Tourette syndrome (GTS) and childhood-onset obsessive-compulsive disorder (OCD) are still controversial issues. Most cross-sectional studies confirm a significant association between GTS and the development of an immune response against group A beta-hemolytic streptococcus (GABHS). Moreover, longitudinal retrospective studies suggest that a recent exposure to GABHS might be a risk factor for the onset of tics and obsessive-compulsive symptoms. However, further evidence from longitudinal prospective research is needed to verify whether a temporal association between GABHS infections and symptom exacerbations is a useful and reliable criterion for the diagnosis of PANDAS. In addition, preliminary results suggest that the PANDAS spectrum might be enlarged to include attention deficit/hyperactivity disorder. Although a number of immunological biomarkers have been proposed as markers of the PANDAS variant, at present, none of these has been conclusively proved useful to diagnose and monitor disease course in children with a suspicion of PANDAS. Finally, despite their empirical use in community settings, we still lack conclusive, evidence-based data regarding the usefulness of antibiotic and immunomodulatory treatments in children with PANDAS. Given the relevance of this topic for general pediatric health, additional research efforts to solve all the pending issues and the hottest points of debate are warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19913659     DOI: 10.1016/j.jpsychores.2009.07.004

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  20 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

Review 2.  The Streptococcus pyogenes proteome: maps, virulence factors and vaccine candidates.

Authors:  Alexander V Dmitriev; Michael S Chaussee
Journal:  Future Microbiol       Date:  2010-10       Impact factor: 3.165

Review 3.  Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Opin Neurobiol       Date:  2011-05-24       Impact factor: 6.627

Review 4.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

Review 5.  The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward.

Authors:  Tanya K Murphy; Roger Kurlan; James Leckman
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

6.  Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study.

Authors:  Akhgar Ghassabian; Jacoba J Bongers-Schokking; Yolanda B de Rijke; Nina van Mil; Vincent W V Jaddoe; Sabine M P F de Muinck Keizer-Schrama; Herbert Hooijkaas; Albert Hofman; Willy Visser; Gustavo C Roman; Theo J Visser; Frank C Verhulst; Henning Tiemeier
Journal:  Thyroid       Date:  2011-12-16       Impact factor: 6.568

7.  Current trends in drug treatment of obsessive-compulsive disorder.

Authors:  Eric H Decloedt; Dan J Stein
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

8.  Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome.

Authors:  Weerasak Chonchaiya; Flora Tassone; Paul Ashwood; David Hessl; Andrea Schneider; Luis Campos; Danh V Nguyen; Randi J Hagerman
Journal:  Hum Genet       Date:  2010-09-01       Impact factor: 4.132

Review 9.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

Review 10.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.